Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve

Inki Moon, Tae-Hwa Go, Jang Young Kim, Dae Ryong Kang, Suk Ho Sohn, Hyun-Jung Lee, Jae-Woong Choi, Jun-Bean Park, Ho-Young Hwang, Hyung-Kwan Kim, Yong-Jin Kim, Kyung-Hwan Kim, Seung-Pyo Lee

1 Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea, 2 Department of Biostatistics, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, 3 Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, 4 Department of Precision Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea, 5 Department of Cardiovascular Thoracic Surgery, Seoul National University Hospital, Seoul, Republic of Korea, 6 Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea

* sproll1@snu.ac.kr

Abstract

Background
Non-vitamin K direct oral anticoagulant (DOAC) is effective for prevention of embolic events in nonvalvular atrial fibrillation (AF) patients. However, the effectiveness and safety of DOAC in AF patients who have bioprosthetic heart valve (BPHV) is largely unknown.

Methods
We retrospectively identified patients with AF and BPHV, using the diagnostic code and medical device and surgery information from the Korean National Health Insurance Service database, between 2013 and 2018. A 1:2 propensity score-matched cohort (n = 724 taking warfarin; n = 362 taking DOAC) was constructed and analyzed for the primary clinical outcome, a composite of ischemic stroke and systemic embolism. Important secondary outcomes included major bleeding, all-cause death, and the net clinical outcome, defined as a composite of all embolic events, major bleeding, and death.

Results
The mean age was 78.9±6.8 years old, and 45% (n = 489) were male. The mean CHA2DS2-VASc score was 4.7±1.4. DOAC was non-inferior to warfarin for preventing ischemic stroke and systemic embolism (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.56–2.34), major bleeding (HR 0.80, 95% CI 0.32–2.03) and all-cause death (HR 1.09, 95% CI 0.73–1.63). As for the net clinical outcome, DOAC was also similar to warfarin (HR 1.06, 95% CI 0.76–1.47). These outcomes were not different in various subgroups analyzed.
Conclusion
In this nationwide Korean AF population with a BPHV, DOAC was at least as effective and safe as warfarin for the prevention of systemic embolic events. These results suggest that DOAC may be an excellent alternative to warfarin in AF patients with BPHV.

Introduction
Atrial fibrillation (AF) is an independent risk factor for ischemic stroke and systemic embolism (ISSE). Therefore, the prevention of ISSE is a major objective of treatment in AF patients [1]. After several pivotal randomized clinical trials that evaluated the efficacy and safety of non-vitamin K direct oral anticoagulants (DOAC) in AF [2–5], DOAC has gained popularity for ISSE prevention in AF patients. However, these trials excluded those with significant valvular heart disease, and there is limited evidence on the use of DOAC for AF patients with various comorbidities [1].

In recent expert consensus statements [6], the use of DOAC has been recommended in AF patients with valvular heart disease based on post-hoc analysis of randomized clinical trials [7], and retrospective studies [8,9]. However, again, there are exceptions such as those with significant mitral stenosis and mechanical heart valves. Although patients with bioprosthetic heart valve (BPHV) are also possible candidates of DOAC use, the evidence supporting this is limited—an observational report of similar thromboembolic risk in those with BPHV compared to those with nonvalvular AF [10], and small-sized post-hoc analysis of randomized trials and pilot studies in these specific patients [11]. Recently, a randomized trial showed the non-inferiority of rivaroxaban compared to warfarin in this group [12]; however, the evidence from real-world practice is still short.

In this analysis, we hypothesized that DOAC would be as effective as warfarin for the prevention of ISSE in patients with AF and BPHV. The objective of this study was to investigate the effectiveness and safety of DOAC compared to warfarin, specifically in AF patients with concomitant BPHV, using a Korean nationwide cohort.

Methods
This study analysis plan was approved by the Seoul National University Hospital Institutional Review Board (E-1903-048-1016). This research was done without patient involvement.

Data source
We used the national claims data established by the National Health Insurance Service of Korea for the current retrospective observational analysis. The database has access to all medical records of the entire nationwide Korean population covered by the obligatory National Health Insurance Service and Medical Aid program. Each patients’ sociodemographic information, diagnoses, procedures and surgery, and prescription records are contained in the database. Diagnoses in this database are coded using the International Classification of Disease-10th Revision-Clinical Modification (ICD-10-CM) nomenclature. Patients were not invited to comment on the study design and were not consulted to develop patient-relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.
Study cohort

Using codes for medical devices and surgical procedures (S1 Table), we included adult patients who had BPHV newly implanted between January 2013 to December 2018. Patients who had concomitant mechanical heart valve or had previous prosthetic valvular replacement (ICD-10-CM code Z952-954) were excluded. Thereafter, we identified AF patients (ICD-10-CM code I480-484, I489) who had oral anticoagulants prescribed for at least 30 days, either DOAC or warfarin. We initially constructed the entire cohort with AF patients who used either the DOAC or warfarin, and then, the patients were propensity score-matched in a 1:2 manner. The detailed patient enrollment flow is presented in Fig 1.

Defining the comorbidities and outcomes

Comorbidities were defined using the ICD-10-CM codes (S2 Table). The use of antiplatelet, the type of heart valve used for replacement, and the type of replacement operation were identified using the code of prescription, procedure, and surgery. The CHA$_2$DS$_2$-VASc score was calculated for each patient by using the known criteria [1].

We evaluated 4 major clinical outcomes (S3 Table) to analyze the effectiveness and safety of DOAC versus warfarin [8,13]. The primary outcome was a composite of hospitalization under the diagnosis of ISSE after three weeks of anticoagulation. For important secondary outcomes, major bleeding (intracranial hemorrhage + gastrointestinal bleeding), all-cause death, and the net clinical outcome—a composite of ISSE, major bleeding, and all-cause death—were also defined by the ICD-10-CM codes. Follow-up was initiated from the date of the index treatment by either the DOAC or warfarin and ended with either the occurrence of a clinical event or the end of the study period (December 31, 2018), whichever came first. The nationwide insurance coverage for DOAC use was expanded from July 2015; therefore, the difference in follow-up duration existed between the two groups. We performed an analysis with the
restriction of the follow-up period to 18-month in a propensity score-matched cohort to adjust the difference.

**Sensitivity and subgroup analyses**

Sensitivity analysis was performed using a multivariable Cox-proportional regression method with the entire cohort, adjusting for possible variables that could further affect the outcomes, such as antiplatelet and types of BPHV. Additionally, we performed a sensitivity analysis for overall events during the entire follow-up duration in the propensity score-matched cohort.

To test for possible interaction between the use of DOAC and the specific subgroups, subgroup analyses were performed on the basis of several baseline characteristics, including age, sex, CHA$^2$DS$_2$-VASc score. In the age subgroup analysis, we categorized patients into three groups as follows: age of <65, 65–74, and ≥75 years old. Regarding the CHA$^2$DS$_2$-VASc score, we divided the total study population into two groups: 0–2 and ≥3 points.

**Statistical analysis**

We used the propensity score matching method to reduce the effect of treatment-selection bias and the potential confounding factors between the two treatment groups (DOAC versus warfarin). The propensity for each treatment group was generated using a logistic regression method including the entire clinical variables: age, sex, hypertension, diabetes mellitus, dyslipidemia, heart failure, vascular disease, chronic kidney disease, chronic obstructive lung disease, CHA$^2$DS$_2$-VASc score, use of antiplatelet, and any previous history of stroke, intracranial hemorrhage, gastrointestinal bleeding. The balance of each covariate between the two treatment groups was evaluated using the absolute standardized difference. An absolute standardized difference <10% was considered to balance each covariate between the two treatment groups. We matched the DOAC and warfarin group in a 1:2 ratio.

The cumulative event rates between the DOAC and warfarin groups were demonstrated using Kaplan-Meier censoring estimates and compared using the Prentice-Wilcoxon test. Event rates were described as the number of events per 100 person-years. The risk for 4 clinical outcomes in the two treatment groups was presented with hazard ratios (HR) and the corresponding 95% confidence intervals (CI) calculated by Cox proportional hazard models. For the sensitivity analysis and subgroup analyses, we used a multivariable Cox proportional hazard regression method adjusting for all available factors. All $P$-values were two-sided and a $p$-value <0.05 was considered statistically significant. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).

**Results**

**Baseline characteristics of the study population**

We identified 1,842 oral anticoagulant users with AF and BPHV between 2013 and 2018. The study population was distributed into two groups; 362 patients who have dispensed DOAC and 1,480 warfarin users. In the entire cohort, the DOAC group was older, and the prevalence of comorbidities was higher than the warfarin group (S4 Table).

After 1:2 propensity score-matching, a total cohort of 1,086 patients was constructed, and the baseline characteristics of the cohort are presented in Table 1. All differences of baseline covariates were less than the absolute standardized difference of 10%, with well-distributed individual propensity scores and balanced assessments after matching (S1 Fig). The mean age was 78.9±6.8 years old, and 489 (45.0%) patients were male. The mean CHA$^2$DS$_2$-VASc score was 4.7±1.4. The aortic valve was replaced with a BPHV in 700 (64.5%) and mitral valve in 461
Patients. The warfarin group received more surgical BPHV than the DOAC group (97.2% vs. 77.1%, \( P < 0.001 \)). The time interval between the valve replacement and the study enrollment was longer in the DOAC group (S5 Table).

### Clinical outcomes in patients with AF and BPHV

During a mean 1.2 years follow-up, there were 19 ISSE events in the DOAC and 43 in the warfarin group. The event rate for ISSE was 4.85 per 100 person-years for DOAC versus 4.66 per 100 person-years for the warfarin group (Table 2). The risk of ISSE was not different (HR 1.14, 95% CI 0.56–2.34, \( P = 0.715 \); Table 2, Fig 2A).

As for the safety outcomes, major bleeding occurred at an event rate of 2.77 per 100 person-years for DOAC and 2.13 per 100 person-years for warfarin group, which was also not statistically different (HR 0.80, 95% CI 0.32–2.03; Table 2, Fig 2B). The event rate for all-cause death

---

**Table 1. Baseline characteristics of patients with AF and BPHV according to oral anticoagulant.**

|                      | Warfarin  | DOAC     | P-value | ASD (%) |
|----------------------|-----------|----------|---------|---------|
|                      | (n = 724) | (n = 362) |         |         |
| Age, years           |           |          |         |         |
| &lt; 65              | 14 (1.9%) | 10 (2.8%)| 0.958   |         |
| 65–74                | 151 (20.9%)| 74 (20.4%)|         |         |
| &gt; 75              | 559 (77.2%)| 278 (76.8%)|         |         |
| Male                 | 325 (44.9%)| 164 (45.3%)| 0.233   | -0.83   |
| Comorbidities        |           |          |         |         |
| Hypertension         | 643 (88.8%)| 324 (89.5%)| 1.000   | 2.22    |
| Diabetes             | 359 (49.6%)| 181 (50.0%)| 0.579   | 0.83    |
| Dyslipidemia         | 611 (84.4%)| 306 (84.5%)| 0.800   | 0.38    |
| Heart failure        | 464 (64.1%)| 236 (65.2%)| 0.845   | 2.31    |
| Vascular disease     | 192 (26.5%)| 101 (27.9%)| 0.689   | 3.10    |
| Chronic kidney disease| 68 (9.4%)   | 36 (9.9%)   | 0.431   | 1.87    |
| End-stage renal disease| 4 (0.6%)   | 2 (0.6%)   | 1.000   | 0.00    |
| COPD                 | 213 (29.4%)| 113 (31.2%)| 0.469   | 3.90    |
| Previous stroke      | 35 (4.8%)  | 19 (5.3%)  | 0.706   | 1.89    |
| Previous ICH         | 149 (20.6%)| 89 (24.6%)  | 0.152   | 9.58    |
| Previous GI bleeding | 26 (3.6%)  | 12 (3.3%)  | 0.225   | -1.51   |
| CHA2DS2-VASc score   | 4.7 ± 1.4 | 4.7 ± 1.4 | 0.750   | 2.12    |
| 0–2                  | 42 (5.8%)  | 22 (6.1%)  | 0.964   |         |
| &gt; 2               | 682 (94.2%)| 340 (93.9%)|         |         |
| Antipla telet        | 424 (58.6%)| 211 (58.3%)| 0.493   | -0.56   |
| Replacement valve    |           |          | 0.212   |         |
| Aortic valve         | 451 (55.6%)| 249 (62.9%)|         |         |
| Mitral valve         | 328 (40.4%)| 133 (33.6%)|         |         |
| Others*              | 32 (3.9%)  | 14 (3.5%)  |         |         |
| Replacement type     |           |          | &lt;0.01 |         |
| Surgical             | 704 (97.2%)| 279 (77.1%)|         |         |
| Transcatheter        | 20 (4.1%)  | 83 (22.9%) |         |         |

Values are mean ± standard deviation or %.

* Other valvular disease included tricuspid valve and pulmonary valve.

Abbreviation: AF, atrial fibrillation; ASD, absolute standardized difference; BPHV, bioprosthetic heart valve; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; ICH, intracranial hemorrhage; DOAC, non-vitamin K antagonist direct oral anticoagulant.

https://doi.org/10.1371/journal.pone.0268113.t001
was 12.62 per 100 person-years for the DOAC and 10.23 per 100 person-years for warfarin group, which was again similar between the two groups (HR 1.09, 95% CI 0.73–1.63; Table 2, Fig 2C). As for the net clinical outcome, defined as a composite of ISSE, major bleeding, and all-cause death, the DOAC group was also not different compared to the warfarin group (HR 1.06, 95% CI 0.76–1.47; Table 2, Fig 2D).

Sensitivity and subgroup analysis

Consistent results were demonstrated by the sensitivity analysis that further adjusted for other covariates. Again, the DOAC group was similar to warfarin in terms of the 4 clinical outcomes (S6 Table). When we also analyzed the overall events over the entire duration of follow-up, the results were also consistent with the main analysis (S7 Table).

The crude incidences and HR of endpoints in the DOAC and the warfarin users by age, sex, and CHA\textsubscript{2}-DS\textsubscript{2}-VASc score subgroups are presented (S8 Table). There were no significant interactions with respect to ISSE, major bleeding, all-cause death, and the net-clinical outcome between the treatment allocation and the various subgroups.

Discussion

In this study, we analyzed the effectiveness and safety of DOAC for ISSE prevention in AF patients with BPHV compared to warfarin. In the propensity score-matched cohort, the event rates of ISSE, major bleeding, all-cause death, and the net clinical outcome were similar between the two groups. Our main finding is that DOAC has comparable effectiveness and safety as warfarin for ISSE prevention in AF patients with BPHV.

Recently, the use of BPHV has become more and more popular than a mechanical valve [14]. Acquired valvular heart disease increases with age [15,16], and guidelines recommend the use of BPHV than mechanical valve for valvular surgery in elderly patients (>65 years old for aortic valve or >70 years old for mitral valve). Moreover, the development of transcatheter aortic valve replacement has allowed the surgeons to consider a BPHV at a younger age more actively, with the option of the valve-in-valve procedure later on [17]. Although data on the epidemiology of patients who have both AF and valvular heart disease is limited, the prevalence

Table 2. Event numbers, incidence rates, and hazard ratios of 4 clinical outcomes in DOAC versus warfarin groups.

| GROUP                              | N  | Event | Duration (years) | Event Rate* | Hazard Ratios (95% CI) | P-value |
|------------------------------------|----|-------|------------------|-------------|------------------------|---------|
| **Ischemic stroke + Systemic embolism** |    |       |                  |             |                        |         |
| Warfarin                          | 724 | 43    | 922.7            | 4.66        | 1(Ref.)                |         |
| DOAC                              | 362 | 19    | 391.7            | 4.85        | 1.14 (0.56–2.34)       | 0.715   |
| **Major bleeding**                |    |       |                  |             |                        |         |
| Warfarin                          | 724 | 20    | 941.2            | 2.13        | 1(Ref.)                |         |
| DOAC                              | 362 | 11    | 397.5            | 2.77        | 0.80 (0.32–2.03)       | 0.638   |
| **All-cause death**               |    |       |                  |             |                        |         |
| Warfarin                          | 724 | 98    | 957.7            | 10.23       | 1(Ref.)                |         |
| DOAC                              | 362 | 51    | 404.0            | 12.62       | 1.09 (0.73–1.63)       | 0.680   |
| **Net clinical outcome**          |    |       |                  |             |                        |         |
| Warfarin                          | 724 | 167   | 885.3            | 18.86       | 1(Ref.)                |         |
| DOAC                              | 362 | 84    | 370.1            | 22.70       | 1.06 (0.76–1.47)       | 0.739   |

*Incidence rate is presented as per 100 person-years.

Abbreviation: AF, atrial fibrillation; BPHV, bioprosthetic heart valve; CI, confidence interval; DOAC, non-vitamin K antagonist direct oral anticoagulant.

https://doi.org/10.1371/journal.pone.0268113.t002
of AF increases dramatically with age [18,19]. Therefore, AF patients with BPHV will inevitably increase in elderly patients, with physicians encountering these patients more and more frequently and facing the clinical enigma of what drugs to use to prevent ISSE in these patients.

**DOAC use in AF patients with BPHV**

To date, there is limited evidence to support the use of DOAC instead of warfarin in AF patients with BPHV. Recently, subclinical leaflet thickening and/or thrombosis has been demonstrated in BPHV [20], suggesting the need for effective measures to prevent thromboembolic events. Although the risk of thromboembolic events may be reduced by warfarin in patients with BPHV [10,21], a recent randomized trial has shown disappointing results with rivaroxaban in patients with the transcatheter aortic valve [22]. The study sought to investigate the impact of rivaroxaban 10mg for preventing thromboembolic events after transcatheter aortic valve replacement without established indication of oral anticoagulation, such as AF. As
such, it is difficult to extrapolate the results of this trial to explain our study results. In those with mechanical heart valves, dabigatran has also been shown to be inferior to warfarin [23]. These findings demonstrate that non-inferior or superior results of DOAC over other anticoagulants or antiplatelets in nonvalvular AF do not always warrant the same efficacy and safety in other groups, especially in those with valvular heart disease or prosthetic heart valves.

Although DOAC seemed to be non-inferior to warfarin in post-hoc analysis of pivotal randomized trials in patients with AF [11,24], these results should be taken cautiously because of the limited number of BPHV patients and clinical events for each group. Recently, the evidence for non-inferiority of rivaroxaban versus warfarin has been updated from the RIVER trial [12]. However, this study exclusively included patients with AF and bioprosthetic mitral valve replacement. The patients were younger (median 59.3 years) and had a lower risk of stroke and bleeding (CHA$_2$DS$_2$-VASc score = 2.6±1.4, HAS-BLED score = 1.6±0.9) than our study because the RIVER trial excluded high-risk patients. Another randomized trial compared edoxaban and warfarin in patients after surgical bioprosthetic valve replacement or valve repair, regardless of the prevalence of AF [25]. This study also showed the inferiority of edoxaban for preventing thromboembolism during the first 3 months. However, the purpose of the study was to investigate the early postoperative outcomes, which was different from ours, and only 62% of patients had AF. Our results demonstrate that DOAC would be at least as effective as warfarin in preventing embolic events and also comparable in terms of safety for AF patients with BPHV in real-world practice. Additionally, these results were consistent throughout the various subgroups analyzed as well. The strengths of our analysis are that it is the largest observational cohort to date that encompasses AF patients with any BPHV and that the results reflect the safety and effectiveness of DOAC within a real-world, high-risk setting in these patients. It also calls for future large randomized trials to resolve the clinical enigma in this population that is expected to grow significantly in the future.

**Current trend of oral anticoagulation for AF patients with BPHV**

To our knowledge, our study is the largest cohort of AF patients with BPHV who received oral anticoagulants for ISSE prevention [10]. Recent expert consensus statement carefully categorized the patients with BPHV to the group with valvular heart disease that could use DOAC instead of warfarin for ISSE prevention [6]. However, despite these statements, our results also showed that clinicians still prefer warfarin over DOAC for AF patients with BPHV in real-world practice; approximately 80% of patients received warfarin in the entire cohort. Interestingly, the DOAC group was older and had a higher proportion of comorbidities (especially higher prevalence of hypertension, heart failure, and previous intracranial hemorrhage; S4 Table) compared to the warfarin group. This prescription pattern may be because DOAC show better bleeding outcomes than warfarin in Asian patients [26]. Therefore, the physicians in Korea are likely to prescribe DOAC for older and fragile groups.

Although not every DOAC have appropriate antidotes compared to warfarin, it is well known that DOAC does not need monitoring of the therapeutic concentration, is stable in terms of therapeutic serum levels, and leads to better compliance than warfarin. Because our analysis is based on a cohort study, the results should be taken as hypothesis-generating, however, if proven in future prospective studies or trials, the results would definitely have a large impact on the prescription pattern of these drugs.

**Limitations**

First, diagnoses were defined by ICD-10 codes, which carry the inherent limitation of coding errors. However, the definition of AF, comorbidities, and clinical outcomes have been
validated in several previous studies [8,12,27]. Second, although we performed propensity score matching and the two treatment groups well balanced, hidden confounding factors might still exist. In the procedure types of BPHV, the patients with transcatheter aortic valve replacement were higher in the DOAC group. Furthermore, the time interval between the valve replacement and the study enrollment was longer in DOAC group, which may be a confounding factor of the study results. However, the outcomes were similar between the two groups even after adjusting these differences. Third, we could not evaluate the treatment quality of warfarin, an inherent limitation of the claims data. Lastly, as for the types of BPHV, the patients who underwent transcatheter aortic valve replacement were higher in the DOAC group. Although it would have been most ideal to adjust this perfectly, it was impossible because introducing new procedures or drugs (transcatheter aortic valve replacement and DOAC in this case) greatly depends on their induction into the medical insurance system.

**Conclusions**

This nationwide population-based study suggests that DOAC has similar effectiveness and safety as warfarin in AF patients with BPHV for the prevention of ISSE. Therefore, DOAC could be an acceptable alternative to warfarin for ISSE prevention in these patients.

**Supporting information**

S1 Fig. Distribution of propensity scores in DOAC and warfarin groups before and after propensity score matching. (DOCX)

S1 Table. Definitions of prosthetic heart valve. (DOCX)

S2 Table. Definitions of covariates. (DOCX)

S3 Table. Definitions of clinical outcomes. (DOCX)

S4 Table. Entire cohort of patients with AF and BPHV according to oral anticoagulant. (DOCX)

S5 Table. The time interval between valve replacement and enrollment in AF patients with BPHV. (DOCX)

S6 Table. Event numbers, incidence rates, and hazard ratios of 4 clinical outcomes using multivariate Cox regression analysis in DOAC versus warfarin in AF patients with BPHV. (DOCX)

S7 Table. Sensitivity analysis during the whole follow-up period. (DOCX)

S8 Table. Number of events, crude event rates and hazard ratios according to various subgroups in AF patients with BPHV. (DOCX)
Author Contributions

Conceptualization: Hyun-Jung Lee, Hyung-Kwan Kim, Yong-Jin Kim, Seung-Pyo Lee.

Data curation: Tae-Hwa Go.

Formal analysis: Tae-Hwa Go, Dae Ryong Kang.

Methodology: Tae-Hwa Go, Jang Young Kim, Dae Ryong Kang, Suk Ho Sohn, Hyun-Jung Lee, Jun-Bean Park, Hyung-Kwan Kim.

Resources: Jang Young Kim, Suk Ho Sohn, Jun-Bean Park.

Supervision: Yong-Jin Kim, Kyung-Hwan Kim.

Validation: Jae-Woong Choi, Ho-Young Hwang.

Visualization: Inki Moon.

Writing – original draft: Inki Moon.

Writing – review & editing: Jae-Woong Choi, Ho-Young Hwang, Seung-Pyo Lee.

References

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38):2893–962. Epub 2016/08/28. https://doi.org/10.1093/eurheartj/ehw210 PMID: 27567408.

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51. Epub 2009/09/01. https://doi.org/10.1056/NEJMoa090561 PMID: 19717844.

3. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093–104. Epub 2013/11/21. https://doi.org/10.1056/NEJMoa1310907 PMID: 24251359.

4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981–92. Epub 2011/08/30. https://doi.org/10.1056/NEJMoa1107039 PMID: 21670076.

5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–91. Epub 2011/08/13. https://doi.org/10.1056/NEJMoa1009638 PMID: 21830957.

6. Lip GYH, Collet JP, Caterina R, Fauchier L, Lane DA, Larsen TB, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvar Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace. 2017; 19(11):1757–8. Epub 2017/11/03. https://doi.org/10.1093/europace/eux240 PMID: 29096204.

7. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. J Am Coll Cardiol. 2017; 69(11):1363–71. Epub 2017/03/18. https://doi.org/10.1016/j.jacc.2016.12.038 PMID: 28302287.

8. Moon I, Lee SR, Choi EK, Lee E, Jung JH, Han KD, et al. Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease. J Clin Med. 2019; 8(10). Epub 2019/10/09. https://doi.org/10.3390/jcm8101624 PMID: 31590290.

9. Noseworthy PA, Yao X, Shah ND, Gersh BJ. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol. 2016; 209:181–3. Epub 2016/02/21. https://doi.org/10.1016/j.ijcard.2016.02.005 PMID: 26896618.

10. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2016; 115(5):1056–63. Epub 2016/02/05. https://doi.org/10.1160/TH16-01-0007 PMID: 26843425.
11. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart. 2019; 105(18):1432–6. Epub 2019/06/17. https://doi.org/10.1136/heartjnl-2019-314767 PMID: 31203254.

12. Guimarães HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med 2020; 383:2117–26. Epub 2020/11/14. https://doi.org/10.1056/NEJMoa2029603 PMID: 3196155.

13. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, et al. Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. J Am Coll Cardiol. 2019; 73(10):1123–31. Epub 2019/03/16. https://doi.org/10.1016/j.jacc.2018.12.047 PMID: 30871695.

14. Fujita B, Ensminger S, Bauer T, Mollmann H, Beckmann A, Bekeredjian R, et al. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 patients. Eur J Cardiothorac Surg. 2018; 53(3):552–9. Epub 2017/12/01. https://doi.org/10.1093/ejcts/ezx408 PMID: 29190355.

15. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol. 2011; 8(3):162–72. Epub 2011/01/26. https://doi.org/10.1038/nrcardio.2010.202 PMID: 21263455.

16. Kim MS, Cho SJ, Park SJ, Cho SW, Choi SH, Kim HS, et al. Frequency and Clinical Associating Factors of Valvular Heart Disease in Asymptomatic Korean Adults. Sci Rep. 2019; 9(1):16741. Epub 2019/11/16. https://doi.org/10.1038/s41598-019-53277-0 PMID: 31729795.

17. Hirji SA, Percy ED, Zogg CK, Malarzycz A, Harloff MT, Yazdchi F, et al. Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes. Eur Heart J. 2020. Epub 2020/05/24. https://doi.org/10.1093/eurheartj/ehaa252 PMID: 32445575.

18. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol. 2017; 236:226–31. Epub 2017/02/25. https://doi.org/10.1016/j.ijcard.2017.02.039 PMID: 28233629.

19. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013; 15(4):486–93. Epub 2012/12/12. https://doi.org/10.1093/europace/eus335 PMID: 23220354.

20. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart. 2019. Epub 2019/11/24. https://doi.org/10.1136/heartjnl-2019-315453 PMID: 31757813.

21. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013; 15(4):486–93. Epub 2012/12/12. https://doi.org/10.1093/europace/eus335 PMID: 23220354.

22. Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valve: an observational study. Lancet. 2017; 389(10087):2383–92. Epub 2017/03/24. https://doi.org/10.1016/S0140-6736(17)30757-2 PMID: 28330690.

23. Christersson C, James SK, Lindhagen L, Ahlsson A, Friberg O, Jeppsson A, et al. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart. 2019. Epub 2019/11/24. https://doi.org/10.1136/heartjnl-2019-315453 PMID: 31757813.

24. Dangas GD, Tijssen JGP, Wohlrle J, Sondergaard L, Gilard M, Mollmann H, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020; 382(2):120–9. Epub 2019/11/17. https://doi.org/10.1056/NEJMoa1911425 PMID: 31733180.

25. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13):1206–14. Epub 2013/09/03. https://doi.org/10.1056/NEJMoa130615 PMID: 23991661.

26. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017; 135(13):1273–5. Epub 2017/02/18. https://doi.org/10.1161/CIRCULATIONAHA.116.026714 PMID: 28209729.

27. Shim CY, Seo J, Kim YJ, Lee SH, Caterina RD, Lee S, Hong GR et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. J Thorac Cardiovasc Surg. 2021; 12(1):1022–2. Online ahead of print. https://doi.org/10.1016/j.jtcvs.2021.01.127 PMID: 32762903.

28. Lip GYH, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal. Int J Cardiol 2015; 180:246–54. https://doi.org/10.1016/j.ijcard.2014.11.182 PMID: 25463377.

29. Lee SR, Choi EK, Han KD, Jung JH, Cha MJ, et al. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease. J Am Coll Cardiol. 2019; 73(25):3295–308. Epub 2019/06/30. https://doi.org/10.1016/j.jacc.2019.04.052 PMID: 31248551.